QURE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
uniQure NV (QURE) is not a strong buy at the moment given the investor's beginner level, long-term strategy, and available capital. While there are some positive developments, the regulatory uncertainty, recent lawsuits, and weak financial performance outweigh the potential upside. A 'hold' recommendation is more suitable until clearer regulatory and financial improvements emerge.
The technical indicators show a neutral stance. The MACD is above zero but contracting, RSI is neutral at 47.616, and moving averages are converging. The stock is trading near its pivot level of 15.837, with key resistance at 17.193 and support at 14.482. No clear bullish or bearish trend is evident.
Analysts from firms like Mizuho, H.C. Wainwright, and Wells Fargo have upgraded the stock recently, citing potential regulatory flexibility and improved outlook for AMT-130 in Huntington's disease.
The departure of FDA official Vinay Prasad is seen as a positive development for the company's regulatory prospects.
The company is facing a class action lawsuit for securities fraud and allegations of failing to disclose material information regarding FDA approval for AMT-
Recent news highlights criticism of AMT-130 as a 'failed therapy,' raising concerns about its future viability.
Financial performance is weak, with net income and EPS significantly declining YoY.
In Q4 2025, revenue increased by 6.65% YoY to $5,568,000, but net income dropped by 49.38% YoY to -$37,086,000. EPS also declined by 60.67% YoY to -$0.59. Gross margin improved slightly to 92.19%. Overall, financial performance shows growth in revenue but significant challenges in profitability.
Analyst sentiment is mixed. While several firms have upgraded the stock and raised price targets (e.g., Mizuho to $35, Wells Fargo to $60), others like Barclays have lowered their targets (e.g., to $25 from $31) due to ongoing regulatory uncertainty. The consensus reflects cautious optimism but significant risks remain.
